Open an Account
search icon
2
NOTIFICATIONS
Best Algo trading app in India
Bigul

NORRIS MEDICINES LTD. - 524414 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39 (3) of the SEBI (Listing Obligation and Disclosure Requirements) LODR Regulation, 2015, this is to inform you that, the RTA has received below request from the shareholder for issue of duplicate share certificates. RTA will advise him/her the necessary procedure. Upon receipt of valid documents executed by him/her, RTA/Company will issue the duplicate share certificates in lieu of original share certificates, as per the particulars furnished below.
19-05-2022
Bigul

NORRIS MEDICINES LTD. - 524414 - Board Meeting Intimation for To Consider Audited Financial Results For The Quarter And Year Ended On 31St March, 2022

 NORRIS MEDICINES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2022 ,inter alia, to consider and approve Audited Financial Results of the Company for the Quarter and year ended 31st March, 2022
16-05-2022
Bigul

NORRIS MEDICINES LTD. - 524414 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayNORRIS MEDICINES LTD. 2CINL24230GJ1990PLC086581 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: VINAY RANA Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: [email protected] Name of the Chief Financial Officer: Iqubal Patel Designation: Chief Financial Officer EmailId: [email protected] Date: 20/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
20-04-2022
Bigul

NORRIS MEDICINES LTD. - 524414 - Submission Of Certificate Under Reg. 40(9) For The Period Ended March 31, 2021

 With regards to the captioned subject please find enclosed herewith the Certificate issued by M/s. Devesh R Desai, Practicing Company Secretary for the period ended March31, 2021.
20-04-2022
Bigul

NORRIS MEDICINES LTD. - 524414 - Statement Of Investor Complaints For The Quarter Ended March 2022

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- VINAY RANADesignation :- Company Secretary and Compliance Officer
05-04-2022
Bigul

NORRIS MEDICINES LTD. - 524414 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 With Reference to the subject matter, please find enclosed a certificate under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 for the period 01st January ,2022 to 31st March, 2022, received from M/s. PurvaSharegistry (I) Pvt. Ltd., Registrar and Share Transfer Agent of our Company.
05-04-2022
Bigul

NORRIS MEDICINES LTD. - 524414 - Revision In Policy On Materiality Of Events & Its Disclosures

 Keeping in view various amendments in the Listing Regulations and SEBI Circular No SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated 22nd November, 2021 regarding Disclosure obligations of listed entities in relation to Related Party Transactions, the Board of Directors of the Company at its meeting held on 12th February, 2022 have adopted a revised Policy, on Materiality of Events and its disclosures to the Stock Exchanges with revision in authorities as well.
13-02-2022
Bigul

NORRIS MEDICINES LTD. - 524414 - Standalone Unaudited Financial Results In Compliance With Regulation 33 Of SEBI (LODR) Reg,Ulations, 2015

 Dear Sir, Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the following : 1. Standalone Unaudited Financial Results of the Company for the Quarter and Nine months ended on 31 st December, 2021. 2. Limited Review Report on Standalone Unaudited Financial Results for the quarter and Nine months ended on 31 st December, 2021 . KindIy take the aforesaid information on your record and oblige.
12-02-2022
Bigul

NORRIS MEDICINES LTD. - 524414 - Board Meeting Outcome for Outcome Of Board Meeting

 Subject: Outcome of Board Meeting Dear Sir/Madam, The Board of directors of the Company on its meeting held on today i.e 12.02.2022 has considered and approved: 1) Standalone Unaudited Financial Results of the Company for the Quarter and Nine month ended on 31 st December, 2021 2) Limited Review Report by Statutory Auditors on Standalone Unaudited Financial Results for the quarter and Nine months ended on 31 st December, 2021. The Board has also discussed the other operational, financial and administrative matters in details and passed the necessary resolutions. Board Meeting commenced at 12: 00 P.M. (IST)and concluded at 01.30 P.M.(IST). Kindly take the aforesaid information on your record and oblige.
12-02-2022
Bigul

NORRIS MEDICINES LTD. - 524414 - Board Meeting Intimation for Consider And Approval Of Unaudited Standalone Financial Results Of The Company For The Quarter And Nine Months Ended On 31St December, 2021

 NORRIS MEDICINES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2022 ,inter alia, to consider and approve With reference to the above subject, the Exchange is hereby informed that a meeting of Board of Directors of the Company is scheduled to be held on Saturday, 12th February, 2022 to consider inter alia, the following: 1. Unaudited Standalone Financial Results of the Company for the Quarter and Nine months ended on 31st December, 2021. Pursuant to Company's Code of Conduct and Prevention of Insider Trading, the Trading Window for the insiders is closed till 48 hours of publication of the Financial Results.
02-02-2022
Next Page
Close

Let's Open Free Demat Account